1. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment. (10th November 2020) Authors: Leutz, A.; Pinter, A.; Thaçi, D.; Augustin, M.; Schuster, C.; Fotiou, K.; Hundemer, H.P.; Saure, D.; Mrowietz, U.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment. (1st March 2021) Authors: Leutz, A.; Pinter, A.; Thaçi, D.; Augustin, M.; Schuster, C.; Fotiou, K.; Hundemer, H.P.; Saure, D.; Mrowietz, U.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis. (31st August 2015) Authors: Fotiou, K.; Hofmann, M.; Kaufmann, R.; Thaci, D. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 12(2015:Dec.) Page Start: 2356 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗